Cancer Stem Cells Market to Accumulate a Valuation of USD 2.9 Billion by 2030, Advancing at a 11.2% CAGR | MarketDigits Richmond, Feb. 07, 2024 (GLOBE NEWSWIRE) -- According to a research report "Cancer Stem Cells Market”, by Mode of action (Targeted Cancer Stem Cell, Stem Cell-based Cancer Therapy {Autologous stem...
Global Oncologists Market
Oncologists Global Market to Reach $27.51 Billion by 2032; Asia-Pacific and North America Lead Growth
January 29, 2024 11:35 ET | Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Oncologists Global Market Opportunities and Strategies to 2032" report has been added to's offering. The global oncologists...
Metastatic Non-Small Cell Lung Cancer Market to Surge with a Potential USD 45 Billion Valuation by 2032, Reveals New Comprehensive Analysis
January 24, 2024 10:28 ET | Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Non-Small Cell Lung Cancer - Market Insight, Epidemiology and Market Forecast -2032" report has been added to's...
Oncology Nutrition Market Experiences Growth with Rise in Personalized and Immuno-nutrition Trends
January 22, 2024 21:28 ET | Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Oncology Nutrition Global Market Report 2024" report has been added to's offering. The recent comprehensive analysis within...
Anti-Cancer Monoclonal Antibodies Market to Reach $95.99 billion by 2028, with Asia Pacific Emerging as Fastest-Growing Region
January 22, 2024 21:08 ET | Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Anti-Cancer MAbS Global Market Report 2024" report has been added to's offering. The Anti-Cancer Monoclonal Antibodies (MAbs)...
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
January 16, 2024 17:01 ET | Adagene Inc.
- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and...
Compass Therapeutics Provides Corporate Update
January 05, 2024 08:00 ET | Compass Therapeutics
We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer...
Groundbreaking Early
Groundbreaking Early-Age Onset Colorectal Cancer Think Tank Aims to Transform Colorectal Cancer Outcomes
November 29, 2023 13:49 ET | Fight Colorectal Cancer
Springfield, Mo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Fight Colorectal Cancer (Fight CRC), a national advocacy organization, is leading a groundbreaking initiative to combat the alarming rise of...
Emergen logo.png
Monoclonal Antibodies Market Size Worth USD 572.62 Billion in 2032 | Emergen Research
November 28, 2023 08:17 ET | Emergen Research
Vancouver, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The global monoclonal antibodies market size was USD 204.42 billion in 2022 and is expected to register a revenue CAGR of 10.8% during the forecast...
Dubai Government Grants Insurance Reimbursement for Biomerica’s EZ Detect™ Colorectal Disease Screening Test
September 26, 2023 08:19 ET | Biomerica, Inc.
IRVINE, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that the Dubai government has officially approved insurance reimbursement for the EZ...